Healthcare

A high-growth engine of Sunshine Healthcare

Sunshine Healthcare’s Medical Devices division has evolved significantly from its modest beginnings, emerging as the fastest-growing business segment within Sunshine Holdings. Over just eight years, it has recorded consistent market share growth, underpinned by a strategic decision in 2017 to separate the medical devices business from the pharmaceuticals division. This move enabled a sharper operational focus and created distinct revenue streams, laying the foundation for sustained expansion now clearly visible in the business's strong performance trajectory.

Today, Sunshine Healthcare is firmly positioned as a leading supplier of surgical, diagnostic, and medical equipment across Sri Lanka’s public and private healthcare sectors. Our comprehensive product portfolio has been built through longstanding partnerships with some of the world’s most respected manufacturers. In the surgical segment, we source advanced wound closure solutions, minimally invasive surgical tools, and cutting-edge equipment from global giants such as Johnson & Johnson, 3M, Coloplast, and ICU Medical. Our diagnostics capabilities are significantly enhanced by collaborations with Siemens Healthineers, GE Healthcare, Cordis, and most recently, Randox—partners who bring innovation and credibility to our offerings. The equipment segment includes critical care solutions such as ethylene oxide sterilizers, blood gas analyzers, incubators, and ICU-grade patient monitoring systems.

The division's consistent growth and expanding market footprint are a testament to its operational excellence, strategic foresight, and unwavering focus on aligning with globally trusted medical device manufacturers. This commitment to quality, reliability, and innovation has cemented Sunshine Healthcare’s position as a vital contributor to Sri Lanka’s healthcare infrastructure.

The Medical Devices division delivered strong results during the year, driven primarily by robust volume growth. With the stabilisation of the US dollar, pricing became more predictable and products more accessible, particularly in the cost-sensitive surgical and diagnostic segments. This volume-driven strategy enabled the division to exceed its budget targets by more than 100%.

Performance was further reinforced by the resilience of our global partner network, which remained intact despite the challenges of recent years. The onboarding of Randox as a principal partner in 2024 significantly expanded our diagnostic and immunochemistry capabilities. Meanwhile, Johnson & Johnson and 3M continued to be the leading revenue contributors, supported by sustained demand for surgical and wound care products. Diagnostic solutions from Siemens and GE also gained momentum, benefiting from the post-crisis recovery in elective procedures and growing emphasis on preventive care.

As Sri Lanka’s economy stabilises and investment in healthcare increases, Sunshine Healthcare’s Medical Devices business is well-positioned for continued, sustainable growth. With a strategic focus on innovation, access, and strong partnerships, the division remains a key enabler in strengthening the nation’s healthcare delivery system.